基因组不稳定性衍生的血浆细胞外囊泡-microRNA 特征作为乳腺癌风险和不良预后的微创预测因子

核心信息

  • 论文英文标题: Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer
  • 期刊: J Nanobiotechnol
  • 发表年份: 2021
  • DOI: 10.1186/s12951-020-00767-3
  • PMID/PMCID: 33436002; PMC7802300

研究概览

Then, we constructed a discovery and validation study with multicenter prospective cohorts. Recent studies have indicated that microRNA (miRNA) regulation in genomic instability (GI) is associated with disease risk and clinical outcome.

核心发现

We identified a GI-derived three miRNA signature (MIR421, MIR128-1 and MIR128-2) in the serum extracellular vesicles of BC patients, which was significantly associated with poor prognosis in all the cohorts tested and remained as an independent prognostic factor using multivariate analyses.

When integrated with the clinical characteristics, the composite miRNA-clinical prognostic indicator showed improved prognostic performance.

772 in GSE73002, GSE41922 and TCGA cohorts, respectively.

Furthermore, circulating EVs from BC patients in the in-house cohort harbored elevated levels of miGISig, with effective diagnostic accuracy.

研究设计

Integrative analysis of miRNA expression and somatic mutation profiles was performed to identify GI-associated miRNAs.

Then, we constructed a discovery and validation study with multicenter prospective cohorts.

The GI-derived miRNA signature (miGISig) was developed in the TCGA discovery cohort (n = 261), and was subsequently independently validated in internal TCGA validation (n = 261) and GSE22220 (n = 210) cohorts for prognosis prediction, and in GSE73002 (n = 3966), GSE41922 (n = 54), and in-house clinical exosome (n = 30) cohorts for diagnostic performance.

Echo Biotech 角色

血浆外泌体分离

关联平台: Exoomics®

关联服务与能力: Biofluid EV Isolation & Purification

关联产品或试剂: 无明确产品引用

参考文献

原始论文: Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer J Nanobiotechnol. 2021. DOI: 10.1186/s12951-020-00767-3. PMID/PMCID: 33436002; PMC7802300.